Carmine Carpenito holds a Doctor of Philosophy (PhD) in Immunology from The University of British Columbia. With a strong academic background, he has ventured into various roles in the pharmaceutical and research sectors.

Carpenito's expertise shines through his current position as the Director of Pre-clinical and Translational Oncology at Stelexis Therapeutics. Prior to this role, he served as a Research Advisor at Eli Lilly and Company, showcasing his diverse experience in the industry.

Before his tenure at Eli Lilly, Carpenito held the role of Principal Scientist at ImClone Systems, a subsidiary of Eli Lilly and Company, where he contributed significantly to the field. His journey in the pharmaceutical domain also includes a position as a Scientist at Lonza, further highlighting his expertise.

In addition to his industry roles, Carpenito has a robust academic foundation. He served as a Research Projects Manager at the University of Pennsylvania, bringing a blend of academic and practical insights to his work. Moreover, his research contributions are underscored by his post-doctoral fellowships at reputable institutions such as the BC Cancer Agency (Terry Fox Laboratory) and UCLA.

With a wealth of experience in immunology and oncology, Carpenito's career trajectory exemplifies a dedication to advancing medical research and therapeutic development. His contributions to the field continue to make a significant impact in the industry.